Session 2: Step-up Dosing and Monitoring for CRS and ICANS in Multiple Myeloma Patients Treated with Bispecifics

Shared insight on the respective roles of a multidisciplinary care team involved in the management of multiple myeloma and associated adverse events.

Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.

A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.

Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.

Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.

A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.

Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.

Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.

Experts in the field of multiple myeloma highlight key takeaways for clinicans to be aware of for infections associated with bispecific antibody multiple myeloma treatments.